NOVEXEL
Novexel is a pharmaceutical company that researches and develops novel class antiinfectives for the treatment of severe and difficult to treat bacterial and fungal infections. The Company has an extensive portfolio of antibacterial and anti-fungal compounds, R&D programs, and intellectual property. Novexel’s focus is on novel antimicrobial compounds with activity against multi-resistantorganisms. Novexel’s expertise in Biology, Medicinal Chemistry, Pharmacology, Microbiology and Clinical Development positions the Company at the forefront of the discovery and development of novel therapies for infectious disease.
NOVEXEL
Social Links:
Industry:
Biotechnology Health Care Medical
Founded:
2004-01-01
Address:
Romainville, Ile-de-France, France
Country:
France
Website Url:
http://www.novexel.com
Total Employee:
1+
Status:
Active
Contact:
33 1 57 14 07 77
Email Addresses:
[email protected]
Total Funding:
118.62 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible LetsEncrypt Content Delivery Network Euro Amazon PHP OpenResty CPanel AdBlock Acceptable Ads
Similar Organizations
Peptor
A biopharmaceutical company engaged in discovery and development of immunotherapeutic drugs to treat diabetes
Current Advisors List
Current Employees Featured
Founder
Investors List
NIF SMBC Ventures
NIF SMBC Ventures investment in Series B - Novexel
Atlas Venture
Atlas Venture investment in Series B - Novexel
Goldman Sachs Investment Partners
Goldman Sachs Investment Partners investment in Series B - Novexel
Novo Ventures
Novo Ventures investment in Series B - Novexel
Neomed Management
Neomed Management investment in Series B - Novexel
Andera Partners
Andera Partners investment in Series B - Novexel
Abingworth
Abingworth investment in Series B - Novexel
Sofinnova Investments
Sofinnova Investments investment in Series B - Novexel
3i Group
3i Group investment in Series B - Novexel
Sofinnova Investments
Sofinnova Investments investment in Series A - Novexel
Official Site Inspections
http://www.novexel.com
- Host name: 199.59.243.228
- IP address: 199.59.243.228
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Novexel"
Novexel - Crunchbase Company Profile & Funding
Novexel is a pharmaceutical company that researches and develops novel class antiinfectives for the treatment of severe and difficult to treat bacterial and fungal infections. The Company has …See details»
Novexel Company Profile 2024: Valuation, Investors, …
Provider of novel antibiotics to treat bacterial and fungal infections. The company develops antibacterial and anti-fungal agents to overcome the problem of microbial resistance. The company focuses on biology, pharmacology, …See details»
Novexel Company Profile - Office Locations, Competitors ... - Craft
Novexel is a company that develops treatments for infectious diseases. It designs antibacterial and anti-fungal agents to address the problem of bacterial resistance. See insights on Novexel …See details»
Novexel - Products, Competitors, Financials, Employees, …
Novexel specializes in antimicrobial research and development, particularly in the areas of antibacterial and antifungal treatments. The company focuses on the discovery and …See details»
Novexel - Funding, Financials, Valuation & Investors - Crunchbase
Novexel SA, a pharmaceutical company, engages in the discovery and development of antibacterial and antifungal agents to treat bacterialSee details»
Novexel — Sofinnova Partners
Novexel was an emerging specialty pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of …See details»
AstraZeneca To Acquire Infection Research Company Novexel And …
Dec 23, 2009 · AstraZeneca has agreed to acquire 100 per cent of Novexel’s shares for $350 million in cash payable at completion and will pay up to an additional $75 million to Novexel …See details»
Novexel - Abingworth LLP
Novexel discovered and developed novel anti-bacterials and anti-fungals. Formed as a spin-out of Aventis Pharma, a subsidiary of Sanofi-Aventis, it inherited an advanced portfolio of anti …See details»
Novexel to be Acquired by AstraZeneca | Fierce Biotech
Dec 23, 2009 · Under the terms of the agreement, AstraZeneca will acquire 100 percent of Novexel's shares for $350 million in cash payable upon completion and will pay up to an …See details»
AstraZeneca acquires Novexel - 2009-12-23 - Crunchbase
Dec 23, 2009 · Acquiring Organization: AstraZeneca AstraZeneca is a pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines. Announced Date …See details»
New Weapon Against Superbugs - American Council on Science …
Jun 19, 2023 · Pfizer has just completed phase 3 trials of a new antibiotic that's active against highly resistant Gram-negative infections. It's a real superbug fighter. But what took so long? …See details»
AZ and Forest tie up to buy Novexel - Financial Times
Dec 23, 2009 · AstraZeneca and Forest, the UK and US pharmaceutical companies, are to pay up to $425m (£266m) to buy Novexel, a private France-based drug company specialising in the …See details»
AstraZeneca to Acquire Infection Research Company Novexel
Jan 2, 2010 · AstraZeneca has entered into an agreement to acquire Novexel, a private infection research company in France, and will collaborate with Forest Laboratories on the future co …See details»
AstraZeneca Snaps Up Antibiotics Company Novexel for US$505 mil.
Dec 24, 2009 · AstraZeneca beefs up its pipeline with the acquisition of French antibiotics specialty company Novexel in a deal worth up to US$505 million. This deal will strengthen its …See details»
Novexel - Crunchbase
Novexel SA, a pharmaceutical company, engages in the discovery and development of antibacterial and antifungal agents to treat bacterialSee details»
AstraZeneca Buying Novaxel For Up To $425 Million
Dec 23, 2009 · AstraZeneca has agreed to acquire Novexel, a French infection research company. The deal includes a $375 million up-front cash payment, plus up to $75 million in …See details»
AstraZeneca to pay up to $505M for Novexel | Fierce Biotech
Dec 23, 2009 · Not to be left out of the late-year deal frenzy, AstraZeneca revealed this morning that it will pay at least $350 million--and as much as $505 million--for Novexel, a French …See details»
Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β ...
Oct 1, 2011 · Diazabicyclooctanes (DBO) are a novel class with a β-lactam-like mode of action. The first DBOs to reach clinical development are β-lactamase inhibitors. DBO β-lactamase …See details»
Novexel - Contacts, Employees, Board Members, Advisors & Alumni
Novexel SA, a pharmaceutical company, engages in the discovery and development of antibacterial and antifungal agents to treat bacterialSee details»
Novexel Starts Phase II Clinical Trial with NXL103 in Adults with …
Nov 9, 2009 · Novexel announces that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and …See details»